What are phage therapies and where are they being used?

Phage therapy is the use of bacteriophages—viruses that naturally infect and kill specific bacteria—to treat bacterial infections.

Because bacteriophages are highly specific, they target only the harmful bacteria causing an infection, often leaving the body’s beneficial microbiome intact. This makes them a promising alternative or complement to traditional antibiotics, especially for infections caused by antibiotic-resistant bacteria ("superbugs").

Where is it being used?

• Clinical Research and Trials: Many countries are currently conducting clinical trials to refine the safety and efficacy of phage therapy. Research centers in the United States, Europe, and elsewhere frequently use it under "compassionate use" or "expanded access" protocols for patients who have exhausted all other antibiotic options.
• Geographic Centers of Excellence:
  • Georgia: The Eliava Institute in Tbilisi is the global pioneer of phage therapy, having used it clinically for nearly a century.
  • Poland: The Phage Therapy Unit in Wrocław is a well-established center for clinical phage treatment in Europe.
  • United States: Institutions like the University of California, San Diego (which established the Center for Innovative Phage Applications and Therapeutics, or IPATH), have been leaders in bringing phage therapy into modern western clinical settings.
• Regulatory Status: While there are no widely approved "off-the-shelf" phage drugs in most Western nations yet, regulatory agencies like the FDA in the U.S. and the EMA in Europe facilitate its use on a case-by-case, patient-specific basis for severe, life-threatening infections.

In summary, it is primarily used today in specialized research hospitals and through medical exemptions for patients facing critical, drug-resistant infections. As the science progresses, the goal is to standardize these therapies for broader medical use.